Table 1.
Demographic and clinical characteristics for adolescents and young adults (15 to 39 years of age) with breast cancer by subtype*, California, 2005 through 2009
|
Total (n = 5,331) |
HR+/HER2-* (n = 2,191) |
HR+/HER2+* (n = 811) |
HR-/HER2+* (n = 469) |
Triple negative (n = 1014) |
Unclassified (n = 846) |
|
|---|---|---|---|---|---|---|
| Characteristics |
n (Col%) |
n (Col%) |
n (Col%) |
n (Col%) |
n (Col%) |
n (Col%) |
| Age at diagnosis |
|
|
|
|
|
|
| 15-29 |
560 (10.5%) |
190 (8.7%) |
88 (10.9%) |
63 (13.4%) |
108 (10.7%) |
111 (13.1%) |
| 30-34 |
1,441 (27.0%) |
525 (24.0%) |
237 (29.2%) |
141 (30.1%) |
303 (29.9%) |
235 (27.8%) |
| 35-39 |
3,330 (62.5%) |
1476 (67.4%) |
486 (59.9%) |
265 (56.5%) |
603 (59.5%) |
500 (59.1%) |
| Race/ethnicity** |
|
|
|
|
|
|
| NH White |
2,247 (42.1%) |
984 (44.9%) |
321 (39.6%) |
193 (41.2%) |
404 (39.8%) |
345 (40.8%) |
| NH Black |
388 (7.3%) |
128 (5.8%) |
60 (7.4%) |
37 (7.9%) |
106 (10.5%) |
57 (6.7%) |
| Hispanic |
1,737 (32.6%) |
645 (29.4%) |
273 (33.7%) |
163 (34.8%) |
378 (37.3%) |
278 (32.9%) |
| NH Asian/Pacific Islander |
914 (17.1%) |
423 (19.3%) |
153 (18.9%) |
74 (15.8%) |
120 (11.8%) |
144 (17.0%) |
| Other/unknown |
45 (0.8%) |
11 (0.5%) |
<5 |
<5 |
6 (0.6%) |
22 (2.6%) |
| Marital status at diagnosis |
|
|
|
|
|
|
| Married |
3,268 (61.3%) |
1,338 (61.1%) |
500 (61.7%) |
320 (68.2%) |
616 (60.7%) |
494 (58.4%) |
| Never married |
1,527 (28.6%) |
639 (29.2%) |
242 (29.8%) |
104 (22.2%) |
287 (28.3%) |
255 (30.1%) |
| Previously married |
380 (7.1%) |
165 (7.5%) |
56 (6.9%) |
31 (6.6%) |
83 (8.2%) |
45 (5.3%) |
| Unknown |
156 (2.9%) |
49 (2.2%) |
13 (1.6%) |
14 (3.0%) |
28 (2.8%) |
52 (6.1%) |
| Tumor grade† |
|
|
|
|
|
|
| Low |
2,090 (39.2%) |
1,288 (58.8%) |
323 (39.8%) |
102 (21.7%) |
91 (9.0%) |
286 (33.8%) |
| High |
2,891 (54.2%) |
821 (37.5%) |
455 (56.1%) |
340 (72.5%) |
888 (87.6%) |
387 (45.7%) |
| Unknown/not stated |
350 (6.6%) |
82 (3.7%) |
33 (4.1%) |
27 (5.8%) |
35 (3.5%) |
173 (20.4%) |
| AJCC stage at diagnosis |
|
|
|
|
|
|
| I |
1,310 (24.6%) |
660 (30.1%) |
170 (21.0%) |
86 (18.3%) |
191 (18.8%) |
203 (24.0%) |
| II |
2,328 (43.7%) |
933 (42.6%) |
354 (43.6%) |
187 (39.9%) |
515 (50.8%) |
339 (40.1%) |
| III |
1,100 (20.6%) |
425 (19.4%) |
214 (26.4%) |
130 (27.7%) |
208 (20.5%) |
123 (14.5%) |
| IV |
313 (5.9%) |
115 (5.2%) |
47 (5.8%) |
47 (10.0%) |
60 (5.9%) |
44 (5.2%) |
| Unknown/not stated |
280 (5.3%) |
58 (2.6%) |
26 (3.2%) |
19 (4.1%) |
40 (3.9%) |
137 (16.2%) |
| Tumor size (cm) |
|
|
|
|
|
|
| <2.00 |
1,987 (37.3%) |
969 (44.2%) |
309 (38.1%) |
147 (31.3%) |
287 (28.3%) |
275 (32.5%) |
| 2.01-5.00 |
2,261 (42.4%) |
915 (41.8%) |
350 (43.2%) |
196 (41.8%) |
500 (49.3%) |
300 (35.5%) |
| >5.00 |
734 (13.8%) |
239 (10.9%) |
115 (14.2%) |
79 (16.8%) |
176 (17.4%) |
125 (14.8%) |
| Microinvasion |
57 (1.1%) |
12 (0.5%) |
9 (1.1%) |
17 (3.6%) |
13 (1.3%) |
6 (0.7%) |
| Diffuse |
54 (1.0%) |
15 (0.7%) |
5 (0.6%) |
7 (1.5%) |
0 |
27 (3.2%) |
| Unknown |
238 (4.5%) |
41 (1.9%) |
23 (2.8%) |
23 (4.9%) |
38 (3.7%) |
113 (13.4%) |
| Lymph nodes involvement |
|
|
|
|
|
|
| No |
2,563 (48.1%) |
1,074 (49.0%) |
333 (41.1%) |
178 (38.0%) |
532 (52.5%) |
446 (52.7%) |
| Positive |
2,647 (49.7%) |
1,098 (50.1%) |
470 (58.0%) |
282 (60.1%) |
468 (46.2%) |
329 (38.9%) |
| Unknown |
121 (2.3%) |
19 (0.9%) |
8 (1.0%) |
9 (1.9%) |
14 (1.4%) |
71 (8.4%) |
| Metastasis status |
|
|
|
|
|
|
| No |
4,880 (91.5%) |
2,050 (93.6%) |
751 (92.6%) |
411 (87.6%) |
936 (92.3%) |
732 (86.5%) |
| Yes |
316 (5.9%) |
115 (5.2%) |
47 (5.8%) |
47 (10.0%) |
61 (6.0%) |
46 (5.4%) |
| Unknown |
135 (2.5%) |
26 (1.2%) |
13 (1.6%) |
11 (2.3%) |
17 (1.7%) |
68 (8.0%) |
| Surgery |
|
|
|
|
|
|
| No |
362 (6.8%) |
103 (4.7%) |
47 (5.8%) |
41 (8.7%) |
64 (6.3%) |
107 (12.6%) |
| Yes |
4,942 (92.7%) |
2,077 (94.8%) |
763 (94.1%) |
428 (91.3%) |
944 (93.1%) |
730 (86.3%) |
| Unknown |
27 (0.5%) |
11 (0.5%) |
<5 |
0 |
6 (0.6%) |
9 (1.1%) |
| Chemotherapy |
|
|
|
|
|
|
| No |
1,250 (23.4%) |
588 (26.8%) |
120 (14.8%) |
67 (14.3%) |
120 (11.8%) |
355 (42.0%) |
| Yes |
3,986 (74.8%) |
1,565 (71.4%) |
678 (83.6%) |
395 (84.2%) |
886 (87.4%) |
462 (54.6%) |
| Unknown |
95 (1.8%) |
38 (1.7%) |
13 (1.6%) |
7 (1.5%) |
8 (0.8%) |
29 (3.4%) |
| Radiation therapy |
|
|
|
|
|
|
| No |
2,818 (52.9%) |
1,110 (50.7%) |
415 (51.2%) |
244 (52.0%) |
503 (49.6%) |
546 (64.5%) |
| Yes |
2,509 (47.1%) |
1,080 (49.3%) |
396 (48.8%) |
225 (48.0%) |
511 (50.4%) |
297 (35.1%) |
| Unknown |
<5 |
<5 |
0 |
0 |
0 |
<5 |
| Neighborhood SES quintile |
|
|
|
|
|
|
| 1, lowest |
875 (16.4%) |
328 (15.0%) |
135 (16.6%) |
73 (15.6%) |
183 (18.0%) |
156 (18.4%) |
| 2 |
997 (18.7%) |
392 (17.9%) |
133 (16.4%) |
97 (20.7%) |
203 (20.0%) |
172 (20.3%) |
| 3 |
1,051 (19.7%) |
411 (18.8%) |
163 (20.1%) |
103 (22.0%) |
197 (19.4%) |
177 (20.9%) |
| 4 |
1,190 (22.3%) |
524 (23.9%) |
178 (21.9%) |
100 (21.3%) |
206 (20.3%) |
182 (21.5%) |
| 5, highest |
1,218 (22.8%) |
536 (24.5%) |
202 (24.9%) |
96 (20.5%) |
225 (22.2%) |
159 (18.8%) |
| Insurance status‡ |
|
|
|
|
|
|
| Private/military insurance |
3,637 (68.2%) |
1564 (71.4%) |
557 (68.7%) |
310 (66.1%) |
680 (67.1%) |
526 (62.2%) |
| Public insurance |
1,109 (20.8%) |
408 (18.6%) |
175 (21.6%) |
109 (23.2%) |
234 (23.1%) |
183 (21.6%) |
| No insurance |
93 (1.7%) |
30 (1.4%) |
16 (2.0%) |
6 (1.3%) |
13 (1.3%) |
28 (3.3%) |
| Unknown | 492 (9.2%) | 189 (8.6%) | 63 (7.8%) | 44 (9.4%) | 87 (8.6%) | 109 (12.9%) |
* Human epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor negative, HER2-negative).
** Non-Hispanic.
† Low grade was defined as tumor grade I and II; high grade was defined as tumor grade III.
‡ Public insurance included Medicaid and other government-assisted programs; private insurance included health maintenance organizations, preferred provider organizations, managed care not otherwise specified, and military care.